Meeting
2013 ASCO Annual Meeting
HM1.24/CD317-directed immunotoxin to eliminate malignant plasma cells in vitro and in vivo.
Authors
Martin Gramatzki
Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University of Kiel, Kiel, Germany
Martin Gramatzki , Matthias Staudinger , Pia Glorius , Katja Klausz , Christian Kellner , Andreas Günther , Roland Repp , Renate Burger , Matthias Peipp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8604)
DOI
10.1200/jco.2013.31.15_suppl.8604
Abstract #
8604
Poster Bd #
56A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.
First Author: Wilson I. Gonsalves
Poster
2018 ASCO Annual Meeting
Relationship of acquired resistance of myeloma cells to bortezomib with Lyn and Src induced inhibition of PP2A and effect of treatment with the tyrosine kinase inhibitor dasatinib.
First Author: Barry Paul
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma.
First Author: Qing Zhou
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4.
First Author: Xin Yu